pharmaquotient.com

60 POSTS0 COMMENTS

http://pharmaquotient.com

Collaboration agreement

Gilead-Tentarix Collaborates to Develop Cancer and Inflammation Therapy for $66M

pharmaquotient.com - 15 August 2023 0

generic

Sandoz Announces Positive Results for Biosimilar Aflibercept

pharmaquotient.com - 15 August 2023 0

Merger & Acquisition

Lilly Acquired Sigilon Therapeutics

pharmaquotient.com - 14 August 2023 0

Regulatory update

JNJ Expands Cancer Portfolio with TALVEY Approval

pharmaquotient.com - 10 August 2023 1

Clinical update

Novartis’ Remibrutinib Improves symptom in chronic spontaneous urticaria

pharmaquotient.com - 9 August 2023 0

Oncology

Astellas invested $50 M in Poseida’s CAR-T Cell Therapy for Cancer

pharmaquotient.com - 8 August 2023 0

Business Strategy

Daiichi Sankyo Decided for RD Novare Closure

pharmaquotient.com - 7 August 2023 0

Weekly News Updates

Weekly News for the Week Ending 5-August-2023

pharmaquotient.com - 6 August 2023 0

Update

US FDA Approves Zurzuvae For Postpartum Depression

pharmaquotient.com - 4 August 2023 1

Regulatory update

U.S. FDA Approves Merck’s ERVEBO®

pharmaquotient.com - 3 August 2023 0

1...456 Page 5 of 6

TOP AUTHORS

constance80t

0 POSTS0 COMMENTS

Neha Tripathi

1 POSTS0 COMMENTS

http://pharmaQuotient.com

pharma analyst

0 POSTS0 COMMENTS

pharmaquotient.com

60 POSTS0 COMMENTS

http://pharmaquotient.com

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

20 September 2024

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

17 September 2024

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

9 September 2024

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

7 September 2024

pharmaquotient.com

TOP AUTHORS

Most Read

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

EDITOR PICKS

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

POPULAR POSTS

Neuralink’s Blindsight: A Breakthrough in Vision Restoration

Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025

Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.

POPULAR CATEGORY

ABOUT US

FOLLOW US